anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a randomized, controlled and single blinded trial. Thirty adults with moderate or severe persistent asthma will be randomly assigned into two groups: Pilates method - PM (training group) or muscle stretching exercises - MSE (control group). All subjects will receive the same educational session and will perform the physical exercise proposed for the group for 12 weeks, 3 times/week, 40-minute sessions. The data normality will be analyzed by Kolmogorov-Smirnov, the variables obtained before interventions will be compared with the Student t-test or Mann-Whitney U-test. Comparisons of the initial and final data on outcomes will be analyzed with repeated measures ANOVA with appropriate post hoc of Holm-Sidak. The significance level will be set to 5% for all tests.
In this study, women with pathologically confirmed HSIL(CIN2, 3) or women with cervical carcinoma in situ or early invasive cancer will be included. All participants will have four follow-up visits at enrollment and at months 6, 12, and 24.
The present invention relates to a composition for treatment of mitochondrial transplantation for immunomodulation and fibrosis control in multiple sclerosis. The present invention confirmed that, when muscle-derived mitochondria are transplanted into an animal model with multiple sclerosis, disease activity of multiple sclerosis is decreased, mitochondrial dysfunction is ameliorated, and autoimmune-related immune cells are controlled. Also, it was confirmed that, in the animal model with multiple sclerosis, mitochondrial transplantation increases a variety of intestinal bacterial flora, increases the phylum  Firmicutes  which are beneficial bacteria, decreases the phylum  Bacterodites  which are harmful bacteria, and increases, at the level of the genus, the genera  Akkermansia  and  Romboutsia , thereby regulating the homeostasis of the intestinal bacterial flora. It was confirmed that mitochondrial transplantation reduces the expression of inflammatory fibrosis factors in keloid patient-derived fibroblasts. Also, it was confirmed that, even in cells where fibrosis is accelerated due to IL-17, mitochondrial transplantation reduces the expression of inflammatory fibrosis factors and induces autophage-activating factors, thereby ameliorating keloids. Also, it was confirmed that, in a keloid patient-derived avatar animal model, mitochondrial transplantation inhibits fibrosis of new tissue. Also, it was confirmed that, in vimentin-immunized systemic sclerosis, mitochondrial transplantation inhibits the expression of autoantibodies and inhibits tissue fibrosis.
PURPOSE: To obtain a compsn. which consists of a mixture composed of sorbitol, saccharose, calcium gluconate. trisodium citrate, lysine and arginine, stabilizes the plasma under low-temp. sterilization and is capable of sterilizing a large volume of plasma at a low temp. CONSTITUTION: This compsn. for stabilizing the plasma under the low-temp. sterilization is obtd. by mixing the sorbitol, the saccharose, the calcium gluconate. the trisodium citrate, the lysine and the arginine. At the time of subjecting the plasma to the low-temp. sterilization, this compsn. is added to the plasma prior to the heating stage and is subjected top the low-temp. sterilization by heating the compsn. for 10 hours at 60 deg.C and, thereafter, the mixture is dialyzed against a buffer soln. contg. trisodium citrate, calcium gluconate, sodium chloride, lysine and arginine, by which saccharides, such as sorbitol and saccharose, the removed from the compsn. and the plasma is stabilized. A large volume of the plasma is thus efficiently subjected to the low-temp. sterilization.
The invention belongs to daily necessities field, and in particular to a kind of preparation method of globe artichoke oral cleansing lotion, concretely comprise the following steps：A. pretreatment of raw material；B. bacterial strain is chosen；C. combined inoculation；D. ferment；E. filter, dry.Globe artichoke oral cleansing lotion has bacteriostasis obtained in the application, can suppress oral cavity spoilage organisms；The pure and fresh acid of its mouthfeel is refreshing, and taste has back sweet, correct oral peculiar smell effect is obvious and persistent；Beneficial bacterium therein can adjust oral cavity flora structure, be conducive to long-time oral cavity fresh and cool；The preparation method of the application is simple, and obtained globe artichoke oral cleansing lotion is naturally safe.
PROBLEM TO BE SOLVED: To obtain the subject new antibody capable of binding to human monocyte chemotactic activation factor (human MCP-1) and suppressing action of MCP-1, free from adverse effect and useful for treating and preventing diseases accompanying inflammation, e.g. idiopathic pulmonary fibrosis, glomerulonephritis and arterial sclerosis. SOLUTION: This monoclonal antibody is bound to human monocyte chemotactic activation factor (human MCP-1). The antibody binds to MCP-1 concerning accentuation and activation of chemotaxis of monocyte and macrophage and suppresses its action and is useful as a treating and preventing agent, etc., of diseases accompanying inflammation reaction in which monocyte and macrophage participates, e.g. idiopathic pulmonary fibrosis, glomerulonephritis and arterial sclerosis.  The monoclonal antibody is obtained by separating blood cells by Ficoll separating liquid from peripheral blood of a normal subject to provide a human mononucleosis fraction, then infecting the fraction with Epstein-Barr virus(EBV) and culturing the fraction and selecting human MCP-1 antibody-producing monocyte from the cultured products and fusing the monocyte with a myeloma cell, culturing the fused cell, selecting a strain which forms colony and culturing the strain.
Subjects with MS treated for at least two years that have less than one relapse per year or who had an increase of \<1.5 points on the Expanded Disability Status Scale (EDSS) (if baseline EDSS was 0) or no increase in EDSS (baseline EDSS ≥1). Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
OBJECTIVES: To systematically report and document Trigeminal Trophic Syndrome (TTS), characterize its clinical presentation, diagnostic tests performed, outline management strategies, outcomes; and highlight the role of otolaryngologists in the tissue diagnosis of this rare syndrome.
DATA SOURCES: PubMed/Medline, Scopus, and Cochrane databases.
REVIEW METHODS: PubMed/Medline, Scopus, and Cochrane databases were systematically reviewed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify all cases of TTS published with an English translation from inception to December 2020.
RESULTS: A total of 142 articles describing 214 patients with TTS were included in the analysis. There was a female predominance (62.9 %) and a median age of 57 (range 1-93) years at presentation. A trigeminal neurological insult was identified in 200 (93.5 %) cases. The most common triggers for TTS were treatment for trigeminal neuralgia (35.7 %) and cerebrovascular accident (21.6 %). Self-inflicted trauma occurred in 137 (64 %) patients. Biopsy was done in 123 (57.5 %) patients. Patient education, barrier devices, and medications to address parasthesias were the most common treatment strategies. The majority of patients (72.5 %) received multimodal therapy. Surgery was performed in 35 (22.7 %) patients. Treatment outcomes were discussed in 120 (56.1 %) patients.
CONCLUSIONS: TTS is a rare condition with poorly understood pathophysiology. It should be suspected in a patient with non-healing facial ulceration and altered sensation within the trigeminal nerve distribution. Biopsy of the ulcer is important to confirm the diagnosis and exclude malignancy. Treatment options include conservative and pharmacologic measures, and less frequently surgery.
The intervention group will take part in mindfulness-based stress reduction (MBSR) program led by a certified MBSR instructor via Zoom. The MBSR program was structured as 11 weeks, taking into account the characteristics of the participants.
Coagulation disorders are described in COVID-19 and long COVID patients. In particular, SARS-CoV-2 infection in megakaryocytes, which are precursors of platelets involved in thrombotic events in COVID-19, long COVID and, in rare cases, in vaccinated individuals, requires further investigation, particularly with the emergence of new SARS-CoV-2 variants. CD147, involved in the regulation of inflammation and required to fight virus infection, can facilitate SARS-CoV-2 entry into megakaryocytes. MCT4, a co-binding protein of CD147 and a key player in the glycolytic metabolism, could also play a role in SARS-CoV-2 infection. Here, we investigated the susceptibility of megakaryocytes to SARS-CoV-2 infection via CD147 and MCT4. We performed infection of Dami cells and human CD34+ hematopoietic progenitor cells induced to megakaryocytic differentiation with SARS-CoV-2 pseudovirus in the presence of AC-73 and syrosingopine, respective inhibitors of CD147 and MCT4 and inducers of autophagy, a process essential in megakaryocyte differentiation. Both AC-73 and syrosingopine enhance autophagy during differentiation but only AC-73 enhances megakaryocytic maturation. Importantly, we found that AC-73 or syrosingopine significantly inhibits SARS-CoV-2 infection of megakaryocytes. Altogether, our data indicate AC-73 and syrosingopine as inhibitors of SARS-CoV-2 infection via CD147 and MCT4 that can be used to prevent SARS-CoV-2 binding and entry into megakaryocytes, which are precursors of platelets involved in COVID-19-associated coagulopathy.
The use of benzodiazepines, including flurazepam hydrochloride capsules, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death [see Drug Abuse and Dependence ( 9.2) ]. 

Before prescribing flurazepam hydrochloride capsules and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of flurazepam hydrochloride capsules, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of flurazepam hydrochloride capsules along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate.
BACKGROUND/AIMS: Gastroenterologists have an important role in the treatment and management of comorbidities related to obesity. Assessment of gastroenterologists' perception and attitude toward obesity was aimed in this study.
MATERIALS AND METHODS: Survey questions were determined for the study. An online questionnaire was prepared afterward. Participants were invited via e-mail by providing them with information about the study. It was ensured that those who accepted the study could access the questionnaire form with the relevant link. Participants who answered all questions were included in the study.
RESULTS: Totally 117 gastroenterologists were included in the study. The proportion of gastroenterologists who thought that obesity complicates the management of gastroenterological diseases and those who thought obesity as a factor that negatively affects the prognosis of gastroenterological diseases was determined as 88.9% and 95.7%, respectively. Among the obese patients, the proportion of those who applied diet therapy, exercise, pharmacotherapy, and endoscopic methods was 94%, 91.5%, 35%, and 37.6%, respectively. The rates of intragastric balloon therapy and intragastric botulinum toxin A injection were 30% and 21.4%, respectively. The proportion of those who agreed that obese patients lost a significant amount of weight with the treatment methods applied was 47.2%. The proportion of participants who agreed that long-term maintenance of weight loss was impossible for most obese patients was 59.8%.
CONCLUSION: To our knowledge, this is the first study that evaluates the perception and attitude of gastroenterologists toward obesity. Our study results show that gastroenterologists think that obesity is a chronic disease and that gastroenterologists should be involved in management of obesity.
The present invention relates to an orally disintegrating tablet of febrifuge and analgesic ibuprofen arginine and a preparing method thereof. The orally disintegrating of ibuprofen arginine according to the invention is composed of active component of ibuprofen arginine and appropriate medical supplementary material. The weight percent is as follows: 20%-60% of ibuprofen arginine, and 40%-80% of supplementary material. The supplementary material comprises the following components: one component or a plurality of components selected from thinning agent (filling agent), disintegrating agent, adhesive, wetting agent, lubricant, flavor correcting agent, colorant and effervescence disintegrating agent. The orally disintegrating of ibuprofen arginine can adopt the flavor correcting agent, mucilage, packing technique or integratedly use the plurality of methods for covering the biting taste of principal agent. The orally disintegrating of ibuprofen arginine of the invention has the advantages of excellent mouth feel, no requirement of water in medicine taking, quick disintegrating in oral cavity, quickly medicine releasing in stomach, guarantee of quick function, better hardness, no requirement of special device in production process and suitability of industrial production.
The invention belongs to the technical field of treating neoplasms by using traditional Chinese medicines. In order to solve the technical problems of big side effects and high recurrence rate, the invention provides a composition for treating digestive system neoplasms such as colon cancer and rectal cancer, and a preparation method of the composition. The composition is prepared from the following components in parts by weight: 30-55 parts of honeysuckle flower, 30-57 parts of herba et gemma agrimoniae, 33-50 parts of herba scutellariae barbatae, 28-60 parts of radix astragali seu hedysari, 28.6-56.2 parts of radix vladimiriae and 60-88 parts of calculus bovis. The preparation method comprises the steps of A. decocting; B. concentrating; C. carrying out alcohol preparation; D. preparing into granules. According to the components of the composition, the honeysuckle flower, the herba scutellariae barbatae and the herba et gemma agrimoniae have the effects of directly inhibiting the neoplasms and removing blood poison; the radix astragali seu hedysari has the effects of tonifying qi and strengthening middle warmer as well as strengthening body resistance and eliminating evil; the radix vladimiriae is used for exerting the effects of regulating vital energy and dispersing depressed liver-energy as well as promoting qi circulation to relieve pain; the calculus bovis factitius has the effects of clearing away heat and toxic materials and eliminating phlegm to calm the frightened; therefore, after being taken by patients with the digestive system neoplasms, the composition enables the vital qi to be gradually recovered, promotes the circulation of qi and blood, strengthens spleen and stomach, recovers appetite and relieves the cancer pain. The composition achieves the satisfactory curative effects of eliminating evil without hurting the vital qi and removing stasis while detoxifying by taking maintaining vital qi and removing cancer toxin as principles of treatment.
BACKGROUND: Patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) present as a main feature ≤50% stenosis upon angiography despite clinical symptoms and biomarker elevation related to acute coronary syndrome. Due to broad availability of high sensitivity troponin testing as well as invasive and non-invasive imaging, this clinical entity receives increasing clinical awareness.
OBJECTIVE: We aimed to investigate the in-hospital work flow and economic impact of MINOCA vs. MICAD (myocardial infarction with obstructive coronary artery disease) patients and related clinical outcomes in a single-center patient collective of a large university heart center in Germany.
METHODS: We retrospectively screened and analyzed all patients who were admitted to our hospital under the suspicion of an acute coronary syndrome within a 12-month period (2017-2018) for further diagnostics and treatment. All included patients showed a pathological troponin elevation and received invasive coronary angiography for acute coronary syndrome. Associated in-hospital costs, procedural and various clinical parameters as well as timelines and parameters of work-flow were obtained.
RESULTS: After screening of 3,021 patients, we included 660 patients with acute coronary syndrome. Of those, 118 patients were attributed to the MINOCA-group. 542 patients presented with a "classical" myocardial infarction (MICAD group). MINOCA patients were less frail, more likely female, but showed no relevant difference in age or other selected comorbidities except for fewer cases of diabetes. In-hospital mortality (11% vs. 0%; p < 0.001) and 30-day mortality (17.3% vs. 4.2%; p < 0.001) after the index event were significantly higher in the "classical" myocardial infarction group (MICAD)- Despite a shorter overall length of hospital stay (9.5 ± 8.7 days vs. 12.3 ± 10.5 days, p < 0.01) with a significantly shorter duration of high care monitoring (intensive/intermediate care or chest pain units) (2.4 ± 2.1 days vs. 4.7 ± 3.3 days, p < 0.01) MINOCA patients consumed a relevant contingent of hospital resources. Thus, in a 12-months period a total sum of almost 300 days was attributed to high care monitoring for MINOCA patients with a mean difference of approximately 50% compared to patients with classical myocardial infarction. With average and median costs of 50% less per index, MINOCA treatment costs were lower compared to the MICAD group in the hospital reimbursement system of Germany. Consequently, MINOCA treatment was not associated with a relevant profit for these expanses and a relevant share of nearly 40% of the total costs was generated due to high care monitoring.
CONCLUSION: In light of lower mortality than MICAD and growing scarcity of staff, financial and capacity resources the clinical symptom complex of MINOCA should be put under particular consideration for refining care concepts and resource allocation.
Clinical Presentation  
Acute overdose with hydrocodone bitartrate and acetaminophen tablets can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations. 

Acetaminophen: In acetaminophen overdosage: dose-dependent, potentially fatal hepatic necrosis is the most serious adverse effect. Renal tubular necrosis, hypoglycemic coma and coagulation defects may also occur. Early symptoms following a potentially hepatotoxic overdose may include: nausea, vomiting, diaphoresis and general malaise. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.

Treatment of Overdose  
In case of overdose, priorities are the reestablishment of a patent and protected airway and institution of assisted or controlled ventilation, if needed. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life-support techniques. 

The opioid antagonists, naloxone or nalmefene, are specific antidotes to respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to hydrocodone bitartrate and acetaminophen tablets overdose, administer an opioid antagonist. Opioid antagonists should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to hydrocodone bitartrate and acetaminophen tablets overdose. 

Because the duration of opioid reversal is expected to be less than the duration of action of hydrocodone bitartrate and acetaminophen in hydrocodone bitartrate and acetaminophen tablets, carefully monitor the patient until spontaneous respiration is reliably re-established. If the response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product’s prescribing information. 

In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be begun with care and by titration with smaller than usual doses of the antagonist.
A chemically modified polysaccharide, which may be chitin/chitosan, cellulose, hydroxyalkyl cellulose or alginate, wherein at least one saccharide residue has grafted thereto a side chain comprising two or more carboxyl groups. One or more of the hydroxy functions on the saccharide or the side chain may be converted to a thiol. The carboxylate groups may be substituted 1,1 (geminally), 1,2 (vicinally) or 1,3 on the side chain and the side chain may be linked to the polysaccharide by an ester or an amide linkage. The carboxylate groups may also be substituted on an unsaturated carbon atom. The modified polysaccharide may complex with Fe<3+> ions selectively over Zn<2+> ions. Also claimed is the modified polysaccharide when incorporated into a therapeutic composition or wound dressing for the treatment of ulcers and lipodermatosclerosis. Also claimed is a process for the production of a modified polysaccharide comprising the step of reacting a polysaccharide with a cyclic anhydride that is substituted with one or more carboxylate groups, particularly cis-aconitic anhydride. The polysaccharide may also be reacted with Lawesson's reagent.
PROBLEM TO BE SOLVED: To obtain a water repellency-treated powder that is smoothly spreadable on the skin with excellent moisture effect and causes no skin irritation. SOLUTION: The objective powder is obtained by treating (A) a powder with (B) a sphingosine derivative and (C) a Lewis acid containing an element in a group IIIB of the periodic table. As the component A, can be used an arbitrary inorganic or organic powder, preferably with an average particle size of 0.1-50 μm. As the component B, are preferably used natural sphingosine derivatives such as (saccharide) ceramide, sphingomyelin, sphingo (saccharide) lipids and amide derivatives such as N-(3-hexadecycloxy-2-hydroxypropyl)-N-2- hydroxyethyldecanamide. The component C used is preferably anhydrous aluminum chloride, boron tribromide and the like. The molar ratio of the component B to the component C is preferably 20:1 to 1:1.
Part A - Single Ascending oral Dose of matching placebo in healthy adult subjects. Part B - Single Ascending oral Dose of matching placebo crossover of PALI-2108 in healthy adult subjects. Part C - Multiple Ascending oral Doses of matching placebo in healthy adult subjects. Part D - (open-label) Multiple Ascending oral Doses of matching placebo in Ulcerative Colitis patients.